# Re: Expression of Concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for Prevention and Treatment of COVID-19 Infection. *Am J Ther.* 2022;29:e232.

### To the Editor:

The Editorial "Expression of Concern"<sup>1</sup> further to the "Commentary"<sup>2</sup> by Rothrock et al regarding our systematic review<sup>3</sup> of clinical trials of ivermectin in COVID-19, raises issues to which we responded<sup>4</sup> rapidly, following the allegations of unreliability made against one large clinical trial.<sup>5</sup> The Editorial "Erratum" now posted with our original article<sup>3</sup> contains hyperlinks not corresponding with the citations in the PDF version<sup>1</sup>; these point in error to irrelevant citations.

We have already responded to the criticisms made by Rothrock et al<sup>2</sup> in a separate letter.<sup>6</sup> Concerning the disputed study,<sup>5</sup> the preprint server *Research Square* posted a notice that concerns expressed by undisclosed complainants were "under formal investigation." Enquiry of the Egyptian Ministry of Education has been acknowledged but without substantive report; at this time, we have no further information.

The imbalance of covariates in the control group of Niaee<sup>7</sup> would not normally be a ground for exclusion of a trial from a systematic review. If such imbalance was detected, then it would justify placing the trial at unclear or high risk of bias, but not for exclusion. As with Elgazzar,<sup>5</sup> the Niaee<sup>7</sup> study was included because the trial met the inclusion criteria of our review protocol.<sup>8</sup> The substantive criticism is that the control group had fewer diagnoses confirmed by the polymerase chain reaction (PCR) test (inclusions being laboratory-confirmed by either PCR or computed tomography (CT) scan). However, all participants had severity attributed from CT, and severity is if anything biased toward slightly fewer severe cases in the control group, corresponding to a bias conservatively against ivermectin. Suspicion that lack of PCR confirmation might imply inclusion of non-COVID-19 cases in controls would likely produce a similarly conservative bias. The slightly lower SpO<sub>2</sub> in the controls appears typical of what randomization in a small group might be expected to deliver, and the body mass index (BMI) distribution appears remarkably uniform across study arms, contrary to the complaint.<sup>2</sup> Vital sign data do appear anomalous, but these are not critical to the mortality assessment, only to the bias assessment.

Subsequent to our article,<sup>3</sup> further clinical trials of ivermectin in COVID-19 have (as expected) also been published. We offer 3 illustrations of mortality results derived with the addition of several new clinical trials, by Vallejos et al<sup>9</sup> and Abd-Elsalam et al,<sup>10</sup> the TOGETHER clinical trial<sup>11</sup> and the recently published I-TECH study.<sup>12</sup> The mortality data for the latter are, unusually, not reported in the main article but are available in the Supplementary Materials.<sup>13</sup> The TOGETHER trial<sup>11</sup> has been formally reported even more recently, and many questions have been raised by multiple parties. Although the Data Sharing Statement promises a complete deidentified patient data set "immediately on publication," the individual patient data as demanded by Rothrock et al<sup>2</sup> (among others) are not yet available. Here, we take data at face value from the article, but using all-cause mortality results from Table S6 of the Supplementary Materials (the mortality reported for our meta-analysis) as published on March 30, 2022 and advised by one Principal Investigator on April 3, 2022. From the Niaee<sup>7</sup> study, we now use mortality stratified by severity, derived from raw data provided to Karale et al,<sup>14</sup> but not available to us at the time of our original article.<sup>3</sup>

Figure 1 shows the results for the mortality outcome, subgrouped by disease severity, including all qualifying randomized trials. Figure 2 shows the consequence of deleting the disputed Elgazzar trial.<sup>5</sup> We have no adequate basis for excluding Niaee<sup>7</sup> but exhibit the results of doing so in Figure 3, which excludes both Elgazzar<sup>5</sup> and Niaee.<sup>7</sup>

The overall point estimates of mortality risk ratio vary from 0.51 (all studies) to 0.65 (Elgazzar excluded) to 0.75 (both Elgazzar and Niaee excluded). Only in the last case do orthodox 95% confidence intervals stray above unity, and by a very small amount. Above

```
www.americantherapeutics.com
```

American Journal of Therapeutics (2022) 29(4)

	lverme		Cont			Risk Ratio	Risk Ratio
Study or Subgroup		Total	Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI
3.1.1 Mild to moderate							
Abd-Elsalam 2021 (1)	3	82	4	82	6.6%	0.75 [0.17, 3.25]	
Ahmed 2020 (2)	0	45	0	23		Not estimable	
Babalola 2020 (3)	0	42	0	20		Not estimable	
Chaccour 2020 (4)	0	12	0	12	2 20/	Not estimable	
Elgazzar 2020 (5)	0	100	4	100	2.2%	0.11 [0.01, 2.04]	
Hashim 2020 (6)	0	48	0	48	7.00/	Not estimable	
I-TECH	3	241	10	249	7.9%	0.31 [0.09, 1.11]	
Lopez-Medina 2021 (7)	0	275	1	198	1.9%	0.24 [0.01, 5.87]	
Mahmud 2020 (8)	0	183 100	3	180	2.1%	0.14 [0.01, 2.70]	
Mohan 2021 (9)	0		0	52	4 10/	Not estimable	
Niaee 2020	1	103 50	10 0	55 50	4.1%	0.05 [0.01, 0.41]	
Petkov 2021 (10)	0	50	4	50	2.2%	Not estimable	
Ravikirti 2021 (11) Rezai 2020 (12)	1	35	4	34	1.9%	0.12 [0.01, 2.09] 2.92 [0.12, 69.20]	
Together Trial 2021	20	679	25	679	1.9%	0.80 [0.45, 1.43]	_
Vallejos 2021	20	250	23	251	6.5%	1.34 [0.30, 5.92]	
Subtotal (95% CI)	4	2300	5	2090	50.8%	0.45 [0.23, 0.88]	
Total events	32	2300	64	2050	5010/0		•
Heterogeneity: $Tau^2 = 0$ .		13 36		(P - 0.1)	5) $\cdot 1^2 - 3$	3%	
Test for overall effect: Z				(1 - 0.1		370	
rest for overall effect. 2	- 2.52 (1 -	- 0.02	<i>,</i>				
3.1.2 Severe covid-19							
Elgazzar 2020 (13)	2	100	20	100	6.8%	0.10 [0.02, 0.42]	
Fonseca 2021 (14)	12	52	25	115	15.1%	1.06 [0.58, 1.94]	
Gonzalez 2021 (15)	5	36	6	37	9.4%	0.86 [0.29, 2.56]	
Hashim 2020 (16)	0	11	6	22	2.4%	0.15 [0.01, 2.40]	· · · · · · · · · · · · · · · · · · ·
Niaee 2020	3	17	1	5	4.1%	0.88 [0.12, 6.73]	
Okumus 2021 (17)	6	36	9	30	11.3%	0.56 [0.22, 1.38]	
Subtotal (95% CI)		252		309	49.2%	0.55 [0.27, 1.12]	•
Total events	28		67				
Heterogeneity: $Tau^2 = 0$ .	38; Chi <sup>2</sup> =	10.58	, df = 5	(P = 0.0)	()(6); $I^2 = 5$	3%	
Test for overall effect: Z							
Total (95% CI)		2552		2399	100.0%	0.51 [0.32, 0.81]	•
Total events	60		131				x
Heterogeneity: $Tau^2 = 0$ .				(P = 0)	$.06); I^2 =$	38%	0.002 0.1 1 10 500
Test for overall effect: Z							Favours ivermectin Favours control
Test for subgroup differe	ences: Chi <sup>2</sup>	= 0.1	4, $df = 1$	(P = 0.	70), $I^2 =$	0%	
<u>Footnotes</u>							
(1) IVM 12mg daily x 3 da							
(1) IVM 12mg daily x 3 da			mg + do	xy x 5	days (24	pts)	
(1) IVM 12mg daily x 3 d (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every	4 pts) or I 84 hrs fo	VM 12	-			pts)	
(1) IVM 12mg daily x 3 d (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every	4 pts) or I 84 hrs fo	VM 12	-			pts)	
(1) IVM 12mg daily x 3 di (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single	4 pts) or I 84 hrs fo dose	VM 12 r 2 wks	s; vs lopi			pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily	4 pts) or I 7 84 hrs fo dose 9 for 4 day	VM 12 r 2 wks s vs H(	s; vs lopi CQ	navir/ri	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3	24 pts) or I 7 84 hrs fo dose 7 for 4 day days + Do	VM 12 r 2 wks s vs H( xy 100	s; vs lopi CQ ) mg BID	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio	24 pts) or I v 84 hrs fo dose v for 4 day days + Do on for 5 da	VM 12 r 2 wks s vs H0 xy 100 ys vs p	s; vs lopi CQ ) mg BID Ilacebo s	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio (8) IVM 6mg once + Doxy	24 pts) or I v 84 hrs fo dose y for 4 day days + Do on for 5 da y 100 mg	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day	s; vs lopi CQ ) mg BID Ilacebo s	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solution (8) IVM 6mg once + Dox (9) IVM 12mg or 24 mg s	24 pts) or I 7 84 hrs fo dose y for 4 day days + Do on for 5 da y 100 mg single dose	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day	s; vs lopi CQ ) mg BID Ilacebo s	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio (8) IVM 6mg once + Dox (9) IVM 12mg or 24 mg s (10) IVM 0.4mg/kg x 3 d	4 pts) or I 4 84 hrs fo dose y for 4 day days + Do on for 5 da y 100 mg ingle dose ays	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day	s; vs lopi CQ ) mg BID Ilacebo s	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio (8) IVM 6mg once + Dox (9) IVM 12mg or 24 mg s (10) IVM 0.4mg/kg x 3 d (11) IVM 12 mg x 2 days	24 pts) or I 7 84 hrs fo dose 9 for 4 day days + Do on for 5 da 9 100 mg single dose ays	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day	s; vs lopi CQ ) mg BID Ilacebo s	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio (8) IVM 0.3mg/kg solutio (8) IVM 6mg once + Doxy (9) IVM 12mg or 24 mg s (10) IVM 0.4mg/kg x 3 d (11) IVM 12 mg x 2 days (12) IVM 0.2mg/kg single	24 pts) or I 7 84 hrs fo dose 9 for 4 day days + Do on for 5 da 9 100 mg single dose ays e dose	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day s	s; vs lopi CQ 0 mg BID Ilacebo s /s	navir/ri x 10 da	tonavir	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio (8) IVM 6mg once + Doxy (9) IVM 12mg or 24 mg s (10) IVM 0.4mg/kg x 3 (11) IVM 0.4mg/kg x 3 (12) IVM 0.2mg/kg single (13) IVM up to 24 mg dai	24 pts) or I 7 84 hrs fo dose 9 for 4 day days + Do on for 5 da 9 100 mg ingle dose ays e dose ily for 4 da	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day s	s; vs lopi CQ ) mg BID Ilacebo s /s	navir/ri x 10 da olution	tonavir	pts)	
· · · · · · · · · · · · · · · · · · ·	24 pts) or I 7 84 hrs fo dose 9 for 4 day days + Do 5 da 9 100 mg 100 m	VM 12 r 2 wks xy 100 ys vs p x 5 day s ys vs F 5 days	s; vs lopi CQ ) mg BID Ilacebo s /s HCQ or CQ x	x 10 da olution 5 days	tonavir ays	pts)	
(1) IVM 12mg daily x 3 da (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single (5) IVM up to 24 mg daily (6) IVM 0.2mg/kg x 2-3 (7) IVM 0.3mg/kg solutio (8) IVM 6mg once + Doxy (9) IVM 12mg or 24 mg s (10) IVM 0.4mg/kg x 3 d (11) IVM 12 mg x 2 days (12) IVM 0.2mg/kg single (13) IVM up to 24 mg dai (14) IVM 14 mg x 3 days	24 pts) or I 7 84 hrs fo dose 9 for 4 day days + Do 10 n for 5 da 9 100 mg 100	VM 12 r 2 wks s vs H( xy 100 ys vs p x 5 day e ys vs H 5 days g depe	s; vs lopi CQ mg BID lacebo s /s fCQ or CQ x nding or	x 10 da olution 5 days	tonavir ays	pts)	

FIGURE 1. Updated mortality meta-analysis including all qualifying trials.

95% CIs in Figures 2 and 3 are 0.96 and 1.03, respectively, in practical terms a minor difference. It is obvious that removal of study data will decrease the overall statistical power of any meta-analysis. However, even when significantly diluted by exclusion of disputed trials, meta-analysis continues to show an improved mortality outcome. Moreover, additional data from the later trials are broadly consistent with the original findings. New data could justify full revision<sup>15</sup> of a systematic review.<sup>3</sup> As previously commented,<sup>6</sup> there are 3 leading options for updating systematic reviews: (1) a living review continuously updated, (2) periodic review subject to criteria<sup>9</sup> (typical intervals for specialist groups are 2–3 years), and (3) a Trial Sequential Analysis. We opted for the latter approach.

Subsequent to our article,<sup>3</sup> Neil and Fenton<sup>16</sup> confirmed by Bayesian hypothesis testing robust

American Journal of Therapeutics (2022) 29(4)

www.americantherapeutics.com




FIGURE 2. Updated mortality meta-analysis excluding Elgazzar.


evidence of a mortality advantage under treatments including ivermectin. Their sensitivity analysis covered the exclusion of Elgazzar,<sup>5</sup> the Niaee<sup>7</sup> trial having been *already* disregarded, not on grounds of reliability, but simply because mortalities were not, at that time, reported<sup>7</sup> by disease severity. Severity being a key component of the hypothesis of Neil and Fenton,<sup>16</sup> data not stratified by severity were of no value. They showed explicitly that the removal of the disputed study<sup>5</sup> (Niaee<sup>7</sup> excluded by design) simply reduced the probability of a favorable risk reduction to around 0.77 or odds of 77:23 that ivermectin treatment offers a mortality benefit. Even under this significant reduction in participants, the conclusion of mortality benefit continued to hold.<sup>16</sup>

The Trial Sequential Analysis<sup>3</sup> and the independent corroboration of Neil and Fenton<sup>16</sup> by different methods provided good evidence that the conclusion of mortality advantage is robust. On the criteria of Garner et al<sup>15</sup> and their decision flowchart (their Figure 1), the question "will the new studies change findings or credibility" could arguably be answered No, however given the controversies raised and the speed with which new data have arisen an updated

www.americantherapeutics.com

American Journal of Therapeutics (2022) 29(4)

	lverme	ctin	Cont	rol		Risk Ratio	Risk Ratio			
Study or Subgroup			Events	Total	Weight	IV, Random, 95% CI	IV, Random, 95% CI			
3.2.1 Mild to moderate (	COVID-19									
Abd-Elsalam 2021 (1)	3	82	4	82	4.7%	0.75 [0.17, 3.25]				
Ahmed 2020 (2)	0	45	0	23		Not estimable				
Babalola 2020 (3)	0	42	0	20		Not estimable				
Chaccour 2020 (4)	0	12	0	12		Not estimable				
Hashim 2020 (5)	0	48	0	48		Not estimable				
I-TECH	3	241	10	249	6.2%	0.31 [0.09, 1.11]				
Lopez-Medina 2021 (6)	0	275	1	198	1.0%	0.24 [0.01, 5.87]				
Mahmud 2020 (7)	0	183	3	180	1.2%	0.14 [0.01, 2.70]	· · · ·			
Mohan 2021 (8)	0	100	0	52		Not estimable				
Niaee 2020	1	103	10	55	0.0%	0.05 [0.01, 0.41]				
Petkov 2021 (9)	0	50	0	50	1 20/	Not estimable				
Ravikirti 2021 (10)	0	55	4	57	1.2%	0.12 [0.01, 2.09]				
Rezai 2020 (11)	1	35	0	34	1.0%	2.92 [0.12, 69.20]				
Together Trial 2021	20	679	25	679	30.4%	0.80 [0.45, 1.43]				
Vallejos 2021 <b>Subtotal (95% CI)</b>	4	250 <b>2097</b>	3	251 <b>1935</b>	4.6%	1.34 [0.30, 5.92]				
the second second second second second	21	2097	50	1922	50.3%	0.68 [0.43, 1.07]				
Total events	31	c 22	50	0.50	N 12 000					
Heterogeneity: $Tau^2 = 0.0$ Test for overall effect: Z =				' = 0.50	J); I <sup>-</sup> = 0%					
3.2.2 Severe COVID-19										
Fonseca 2021 (12)	12	52	25	115	27.7%	1.06 [0.58, 1.94]				
Gonzalez 2021 (13)	5	36	6	37	8.5%	0.86 [0.29, 2.56]				
Hashim 2020 (14)	0	11	6	22	1.3%	0.15 [0.01, 2.40]				
Niaee 2020	3	17	1	5	0.0%	0.88 [0.12, 6.73]				
Okumus 2021 (15) Subtotal (95% CI)	6	36 135	9	30 <b>204</b>	12.2% <b>49.7%</b>	0.56 [0.22, 1.38] <b>0.83 [0.53, 1.30]</b>	•			
Total events Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z =				9 = 0.41	L); $I^2 = 0\%$	i				
Total (95% CI)		2232		2139	100.0%	0.75 [0.55, 1.03]	•			
Total events	54		96							
Heterogeneity: Tau <sup>2</sup> = 0.0 Test for overall effect: Z = Test for subgroup differe Footnotes	= 1.76 (P	= 0.08	)				0.002 0.1 1 10 500 Favours ivermectin Favours control			
(1) IVM 12mg x 3 days + (2) IVM 12mg x 5 days (2 (3) IVM 6mg-12mg every (4) IVM 0.4mg/kg single	4 pts) or l 84 hrs fo dose	VM 12 r 2 wk	s; vs lopi	navir/ri	tonavir	pts)				
(5) IVM 0.2mg/kg x 2-3 ( (6) IVM 0.3mg/kg solutio (7) IVM 6mg once + Doxy	n for 5 da / 100 mg	ys vs p x 5 day	lacebo s							
(8) IVM 12mg or 24 mg s (9) IVM 0.4mg/kg x 3 day (10) IVM 12 mg x 2 days	/s	2								
(11) IVM 0.2mg/kg single (12) IVM 14 mg x 3 days (13) IVM single dose 12m	vs HCQ x 1g or 18m	g depe	nding or	weight	t					
(14) IVM 0.2mg/kg x 2-3 days + Doxy 100 mg BID x 10 days (15) IVM 0.2mg/kg x 5 days (both arms received HCQ, favipiravir, azithromycin)										



review may be justified. This will be offered for publication in due course and include outcomes other than mortality.

Finally, we remark that we know of no clinicians using ivermectin in COVID-19 who would regard it as the sole therapeutic to be used in severe cases. In particular, corticosteroids are now recognized<sup>17</sup> as critically important in late-stage disease. For seriously ill patients, it should be obvious that their survival probability will depend on many details of their management, not simply the use or nonuse of ivermectin. Andrew Bryant, MSc<sup>1</sup> Theresa A. Lawrie, MBBCh, PhD<sup>2</sup> Edmund J. Fordham, PhD, FInstP<sup>2</sup> Scott Mitchell, MBChB, MRCS<sup>2</sup> <sup>1</sup>Population Health Sciences Institute, Newcastle University, Newcastle upon Tyne, United Kingdom <sup>2</sup>EbMCsquared, a Community Interest Company, Bath, United Kingdom

The authors have no conflicts of interest to declare.

All authors were members of the British Ivermectin

American Journal of Therapeutics (2022) 29(4)

www.americantherapeutics.com

#### Letters to the Editor

Recommendation Development (BiRD) panel at the "Evidence to Decision" event convened on February 20, 2021. Mr Bryant and Dr Lawrie were members of the steering group and did not vote. Drs Fordham and Mitchell were ordinary members of the panel. BiRD continues as a public information activity managed by EbMCsquared, a nonprofit Community Interest Company. Dr Fordham is a member of the Health Advisory and Recovery Team (HART), an unincorporated membership association with no financial or material interests in ivermectin or any other medical product. This work is not a project of HART and is not funded in any way by them.

## REFERENCES

- 1. Manu P. Expression of concern for Bryant A, Lawrie TA, Dowswell T, Fordham EJ, Mitchell S, Hill SR, Tham TC. Ivermectin for prevention and treatment of COVID-19 infection. *Am J Ther.* 2022;29:e232.
- Rothrock SG, Weber KD, Giordano PA, et al. Meta-analyses do not establish improved mortality with ivermectin use in COVID-19. "Commentary". *Am J Ther.* 2021;29:e87–e94.
- Bryant A, Lawrie TA, Dowswell T, et al. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. *Am J Therap.* 2021;28:e434–e460.
- Bryant A, Lawrie TA, Fordham EJ. Ivermectin for prevention and treatment of COVID-19 infection: a systematic review, meta-analysis, and trial sequential analysis to inform clinical guidelines. *Am J Ther.* 2021;2828:e434–e460, e573–e576.
- Elgazzar A, Hany B, Youssef SA, et al. Efficacy and safety of ivermectin for treatment and prophylaxis of COVID-19 pandemic. *Res Square*. 2020. Preprint. doi: 10.21203/rs.3.rs-100956/v2.
- Bryant A, Lawrie TA, Fordham EJ, et al. Re: "Commentary" by Rothrock et al. "meta-analyses did not establish improved mortality with ivermectin use in COVID-19". *Am J Ther.* 2021;29:e233–e237.
- 7. Niaee MS, Namdar P, Allami A, et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19

patients: a randomized multi-center clinical trial. Asian Pac J Trop Med. 2021;14:266.

- Bryant A, Lawrie T, Dowsell T, et al. Ivermectin for prevention and treatment of covid-19 (protocol). The evidence-based Medical Consultancy Ltd. 2021. Available at: https://tinyurl.com/cx7pnaxa. Accessed November 11, 2021.
- Vallejos J, Zoni R, Bangher M, et al. Ivermectin to prevent hospitalizations in patients with COVID-19 (IVERCOR-COVID19) a randomized, double-blind, placebo-controlled trial. *BMC Infect Dis.* 2021;21:635.
- Abd-Elsalam S, Noor RA, Badawi R, et al. Clinical study evaluating the efficacy of ivermectin in COVID-19 treatment: a randomized controlled study. *J Med Virol.* 2021; 93:5833–5838.
- 11. Reis G, Silva EA, Silva DC, et al. Effect of early treatment with ivermectin among patients with covid-19. *N Engl J Med.* 2022;386:1721–1731.
- 12. Lim SCL, Hor CP, Tay KH, et al. Efficacy of ivermectin treatment on disease progression among adults with mild to moderate COVID-19 and comorbidities: the I-TECH randomized clinical trial. *JAMA Intern Med.* 2022;182:426–435.
- Lim SCL, Hor CP, Tay KH, et al. Supplement 2. eTable 6: "Post-hoc analyses on clinical outcomes by vaccination status in primary analysis population". *JAMA Intern Med.* 2022. Available at: https://jamanetwork.com/ journals/jamainternalmedicine/fullarticle/2789362. Accessed March 1, 2022.
- Karale S, Bansal V, Makadia J, et al. A meta-analysis of mortality, need for ICU admission, use of mechanical ventilation and adverse effects with ivermectin use in COVID-19 patients. medRxiv. 2021. Preprint. doi: 10. 1101/2021.04.30.21256415.
- 15. Garner P, Hopewell S, Chandler J, et al. When and how to update systematic reviews: consensus and checklist. *BMJ*. 2016;354:i3507.
- Neil M, Fenton N. Bayesian hypothesis testing and hierarchical modeling of ivermectin effectiveness. *Am J Ther*. 2021;28:e576–e579.
- 17. Horby P, Lim WS, Emberson J, et al. Effect of Dexamethasone in hospitalized patients with COVID-19. N Engl J Med. 2020;384:693–704.

# Angiotensin II Receptor Blocking Drugs May Increase Severity of Coronavirus Disease 2019 Infection

### To the Editor:

Human pathogenic coronaviruses bind to their target cells through angiotensin II-converting enzyme (ACE2). Concerns about whether angiotensin II receptor blockers (ARBs) and ACE inhibitors may have deleterious effects on morbidity and mortality in patients with coronavirus disease 2019 (COVID-19) are based on the hypothesis that these drugs would upregulate ACE2 in target cells, thereby facilitating COVID-19 infection.<sup>1,2</sup> However, evidence of positive

www.americantherapeutics.com

American Journal of Therapeutics (2022) 29(4)